Eagle Pharmaceuticals Stock Price, News & Analysis (NASDAQ:EGRX) $5.95 +0.10 (+1.71%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$5.62▼$6.0550-Day Range$5.68▼$15.7752-Week Range$5.53▼$35.93Volume323,828 shsAverage Volume219,535 shsMarket Capitalization$77.29 millionP/E Ratio5.04Dividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Eagle Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingSell1.00 Rating ScoreUpside/Downside185.7% Upside$17.00 Price TargetShort InterestBearish5.24% of Float Sold ShortDividend StrengthN/ASustainability-2.29Upright™ Environmental ScoreNews Sentiment0.07Based on 13 Articles This WeekInsider TradingSelling Shares$295,836 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector255th out of 951 stocksPharmaceutical Preparations Industry105th out of 439 stocks 2.5 Analyst's Opinion Consensus RatingEagle Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Eagle Pharmaceuticals has a forecasted upside of 185.7% from its current price of $5.95.Amount of Analyst CoverageEagle Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.24% of the float of Eagle Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEagle Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Eagle Pharmaceuticals has recently decreased by 3.72%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEagle Pharmaceuticals does not currently pay a dividend.Dividend GrowthEagle Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEagle Pharmaceuticals has received a 53.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Bendamustine", "Dantrolene", and "Pemetrexed" products. See details.Environmental SustainabilityThe Environmental Impact score for Eagle Pharmaceuticals is -2.29. Previous Next 2.3 News and Social Media Coverage News SentimentEagle Pharmaceuticals has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Eagle Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for EGRX on MarketBeat in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eagle Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $295,836.00 in company stock.Percentage Held by Insiders28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.87% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eagle Pharmaceuticals is 5.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Eagle Pharmaceuticals is 5.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.74.Price to Book Value per Share RatioEagle Pharmaceuticals has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Read More EGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EGRX Stock News HeadlinesDecember 1, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Eagle Pharmaceuticals, Inc. - EGRXDecember 1, 2023 | benzinga.comEagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq - Hagens BermanDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 30, 2023 | benzinga.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Eagle Pharmaceuticals, Inc. (EGRX)November 30, 2023 | benzinga.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of InvestorsNovember 30, 2023 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of InvestorsNovember 29, 2023 | tmcnet.comThe Law Offices of Frank R. Cruz Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of InvestorsNovember 29, 2023 | benzinga.comWhy Is Eagle Pharmaceuticals Stock Trading Lower Today?December 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 29, 2023 | markets.businessinsider.comHere's what Wall Street expects from Eagle Pharmaceuticals's earningsNovember 29, 2023 | finance.yahoo.comEagle Pharmaceuticals Announces Management ChangeNovember 29, 2023 | finance.yahoo.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-QNovember 27, 2023 | finance.yahoo.comDown -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a TurnaroundNovember 13, 2023 | benzinga.comEagle Pharmaceuticals's Earnings: A PreviewNovember 10, 2023 | finance.yahoo.comDown -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a TurnaroundNovember 8, 2023 | finance.yahoo.comEagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023November 7, 2023 | morningstar.comEagle Pharmaceuticals Inc EGRXOctober 24, 2023 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Granted Patent for PEMFEXYOctober 24, 2023 | baystreet.caEagle Flies on Patent NewsOctober 23, 2023 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS from CMSOctober 23, 2023 | markets.businessinsider.comA Bird's Eye View Of Eagle PharmaOctober 13, 2023 | finance.yahoo.comImplied Volatility Surging for Eagle Pharmaceuticals (EGRX) Stock OptionsOctober 12, 2023 | finance.yahoo.comShareholders in Eagle Pharmaceuticals (NASDAQ:EGRX) are in the red if they invested five years agoOctober 4, 2023 | finance.yahoo.comEagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual MeetingSeptember 19, 2023 | finance.yahoo.comEagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023August 30, 2023 | finance.yahoo.comEagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) ConferenceAugust 29, 2023 | finance.yahoo.comEagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal WomenSee More Headlines Receive EGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today12/02/2023Next Earnings (Estimated)12/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EGRX CUSIPN/A CIK827871 Webwww.eagleus.com Phone(201) 326-5300FaxN/AEmployees134Year Founded2007Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+185.7%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$1.18 Trailing P/E Ratio5.04 Forward P/E RatioN/A P/E GrowthN/ANet Income$35.64 million Net Margins6.04% Pretax Margin11.33% Return on Equity6.48% Return on Assets3.86% Debt Debt-to-Equity Ratio0.25 Current Ratio2.16 Quick Ratio1.67 Sales & Book Value Annual Sales$316.61 million Price / Sales0.24 Cash Flow$3.86 per share Price / Cash Flow1.54 Book Value$17.94 per share Price / Book0.33Miscellaneous Outstanding Shares12,990,000Free Float9,234,000Market Cap$77.29 million OptionableOptionable Beta0.56 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Scott L. Tarriff (Age 63)Founder, President, CEO & Director Comp: $1.51MMr. Brian Joseph Cahill (Age 54)Chief Financial Officer Comp: $606.06kMr. Ryan DebskiExecutive VP, General Counsel & Chief Compliance OfficerMr. Daniel O'Connor (Age 43)Executive VP, Chief Strategy Officer & Head of Corporate Development Dr. Valentin R. Curt M.D.Senior Vice President of Clinical Drug DevelopmentDr. Gaozhong Zhu Ph.D.Senior Vice President of Pharmaceutical DevelopmentMs. Debra M. HussainSenior VP & Head of CommercialMr. Reed McClungExecutive Vice President of Oncology Business DevelopmentMore ExecutivesKey CompetitorsPepGenNASDAQ:PEPGImmix BiopharmaNASDAQ:IMMXEmergent BioSolutionsNYSE:EBSCue BiopharmaNASDAQ:CUEAnixa BiosciencesNASDAQ:ANIXView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 9,955 shares on 11/30/2023Ownership: 0.757%Deutsche Bank AGSold 48,836 shares on 11/24/2023Ownership: 0.044%Connors Investor Services Inc.Bought 2,500 shares on 11/22/2023Ownership: 0.097%Jacobs Levy Equity Management Inc.Bought 11,586 shares on 11/17/2023Ownership: 0.089%Tudor Investment Corp Et AlBought 28,875 shares on 11/16/2023Ownership: 0.222%View All Insider TransactionsView All Institutional Transactions EGRX Stock Analysis - Frequently Asked Questions Should I buy or sell Eagle Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" EGRX shares. View EGRX analyst ratings or view top-rated stocks. What is Eagle Pharmaceuticals' stock price target for 2024? 1 brokerages have issued 12 month price objectives for Eagle Pharmaceuticals' shares. Their EGRX share price targets range from $17.00 to $17.00. On average, they predict the company's share price to reach $17.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View analysts price targets for EGRX or view top-rated stocks among Wall Street analysts. How have EGRX shares performed in 2023? Eagle Pharmaceuticals' stock was trading at $29.23 at the start of the year. Since then, EGRX shares have decreased by 79.6% and is now trading at $5.95. View the best growth stocks for 2023 here. When is Eagle Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, December 4th 2023. View our EGRX earnings forecast. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to the consensus estimate of $46.70 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 6.48% and a net margin of 6.04%. During the same quarter in the previous year, the business earned $0.51 earnings per share. What guidance has Eagle Pharmaceuticals issued on next quarter's earnings? Eagle Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, October, 6th. The company provided earnings per share (EPS) guidance of $4.40-$4.70 for the period, compared to the consensus estimate of $4.58. The company issued revenue guidance of -. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Schnitzer Steel Industries (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY). Who are Eagle Pharmaceuticals' major shareholders? Eagle Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (8.73%), Adage Capital Partners GP L.L.C. (3.85%), AQR Capital Management LLC (2.18%), Smith Graham & Co. Investment Advisors LP (2.10%), Ameriprise Financial Inc. (1.98%) and Acadian Asset Management LLC (1.82%). Insiders that own company stock include Richard A Edlin and Scott Tarriff. View institutional ownership trends. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:EGRX) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.